Skip to content
Financing

Proceeds from issuance of common stock relating to employee stock plans

Boston Scientific Proceeds from issuance of common stock relating to employee stock plans increased by 305.0% to $81M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 29.6%, from $115M to $81M. Over 4 years (FY 2021 to FY 2025), Proceeds from issuance of common stock relating to employee stock plans shows an upward trend with a 26.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementCash Flow Statement
SectionFinancing
CategoryCapital Allocation
SignalHigher is better
VolatilityStable
First reportedQ1 2018
Last reportedQ1 2026May 1, 2026

How to read this metric

Higher proceeds indicate active employee participation in equity programs and provide a minor source of cash inflow.

Detailed definition

Cash inflows received from employees when they exercise stock options or purchase shares through employee stock purchase...

Peer comparison

Standard metric for companies with broad-based employee equity compensation.

Metric ID: financing_proceeds_from_stock_plans

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$20M$64M$8M$52M$6M$59M$19M$63M$27M$75M$17M$80M$26M$96M$28M$115M$32M$115M$20M$81M
QoQ Change+220.0%-87.5%+550.0%-88.5%+883.3%-67.8%+231.6%-57.1%+177.8%-77.3%+370.6%-67.5%+269.2%-70.8%+310.7%-72.2%+259.4%-82.6%+305.0%
YoY Change-70.0%-7.8%+137.5%+21.2%+350.0%+27.1%-10.5%+27.0%-3.7%+28.0%+64.7%+43.8%+23.1%+19.8%-28.6%-29.6%
Range$6M$115M
CAGR+34.2%
Avg YoY Growth+37.0%
Median YoY Growth+22.1%

Proceeds from issuance of common stock relating to employee stock plans at Other Companies

Frequently Asked Questions

What is Boston Scientific's proceeds from issuance of common stock relating to employee stock plans?
Boston Scientific (BSX) reported proceeds from issuance of common stock relating to employee stock plans of $81M in Q1 2026.
How has Boston Scientific's proceeds from issuance of common stock relating to employee stock plans changed year-over-year?
Boston Scientific's proceeds from issuance of common stock relating to employee stock plans decreased by 29.6% year-over-year, from $115M to $81M.
What is the long-term trend for Boston Scientific's proceeds from issuance of common stock relating to employee stock plans?
Over 4 years (2021 to 2025), Boston Scientific's proceeds from issuance of common stock relating to employee stock plans has grown at a 26.5% compound annual growth rate (CAGR), from $110M to $282M.
What does proceeds from issuance of common stock relating to employee stock plans mean?
Cash received from employees exercising stock options or buying company stock.